NewAmsterdam Pharma (Nasdaq: NAMS) approved inducement equity awards for two non-executive hires on April 1, 2026 under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The grants total 15,000 stock options (exercise price $32.81) and 3,200 restricted stock units, with multi-year vesting schedules tied to continued service.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – NAMS
+3.43%
1 alert
+3.43%News Effect
On the day this news was published, NAMS gained 3.43%, reflecting a moderate positive market reaction.
Inducement options:15,000 sharesOption exercise price:$32.81 per shareOption vesting cliff:25% after 1 year+5 more
8 metrics
Inducement options15,000 sharesAggregate options for two non-executive new hires
Option exercise price$32.81 per shareClosing market price on April 1, 2026 (grant date)
Option vesting cliff25% after 1 yearThen balance vests in 36 monthly installments
Monthly installments36 installmentsRemaining option shares vest monthly after first year
RSU grants3,200 sharesAggregate RSUs for two non-executive new hires
RSU vesting period3 yearsOne-third vests on each annual anniversary
First option vest1-year anniversaryInitial vesting date for 25% of option shares
RSU grant dateApril 1, 2026Grant date under 2024 Inducement Plan
Market Reality Check
Price:$33.68Vol:Volume 725,187 is below 2...
normal vol
$33.68Last Close
VolumeVolume 725,187 is below 20-day average 870,595 (relative volume 0.83x).normal
TechnicalPrice $32.99 is trading above 200-day MA at $30.34, mid-range between 52-week low $14.06 and high $42.00.
Peers on Argus
NAMS gained 2.5%, while high-affinity biotech peers like VKTX (+8.41%), RARE (+6...
NAMS gained 2.5%, while high-affinity biotech peers like VKTX (+8.41%), RARE (+6.65%), MLYS (+5.81%) and CRNX (+3.91%) also traded higher, suggesting broader sector strength beyond this routine inducement grant news.
Common CatalystAt least one peer (RARE) had FDA-related news, while NAMS’ headline concerns standard inducement equity awards rather than a clinical or regulatory catalyst.
Options on 217,000 shares granted to four new hires.
Pattern Detected
Recent NAMS news, including prior inducement grants and conference updates, has often coincided with modest positive price reactions, suggesting the stock has digested routine updates constructively.
Recent Company History
Over recent months, NewAmsterdam has balanced corporate, scientific, and routine HR-related updates. In Feb 2026, full-year 2025 results highlighted substantial cash of $728.9M, ongoing Phase 3 programs, and regulatory filings, with a mild positive reaction. Multiple inducement grant announcements in Feb and Mar 2026 were accompanied by low-single-digit gains. Conference participation and ACC.26 presentation plans underscored continued clinical and scientific visibility. Today’s additional inducement grants fit this pattern of incremental, non-transformational corporate news.
Market Pulse Summary
This announcement details standard equity inducement awards—options on 15,000 shares at an exercise ...
Analysis
This announcement details standard equity inducement awards—options on 15,000 shares at an exercise price of $32.81 plus 3,200 RSUs—granted to two non-executive new hires under the 2024 Inducement Plan. Historically, similar grants for NewAmsterdam have coincided with modest, often positive price moves but have not been major catalysts. Investors may instead focus on the company’s Phase 3 programs, substantial cash position, and upcoming regulatory milestones highlighted in recent earnings and scientific updates.
"approved the grant of inducement share options ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement share optionsfinancial
"approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam’s ordinary shares"
Inducement share options are stock options granted to a new hire as a special incentive to join a company, issued outside the company’s standard employee share plans. For investors, they matter because they create potential future dilution of existing shares and represent a cash‑free form of compensation that signals how much the company values attracting particular talent—like offering a signing bonus paid in future ownership rather than cash.
restricted stock unitsfinancial
"approved the grant of restricted stock units covering an aggregate of 3,200 of NewAmsterdam’s ordinary shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise pricefinancial
"The share options have an exercise price per share equal to $32.81"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement datefinancial
"on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
option award agreementfinancial
"subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement"
A written contract that grants an individual the right to buy company shares at a set price under specific conditions, like how many options they get, when they can exercise them, and when they expire. Think of it like a ticket that becomes valid only after certain milestones; it matters to investors because these agreements affect how many shares may enter the market, management incentives, and a company’s future earnings per share and dilution.
restricted stock unit award agreementfinancial
"subject to the terms and conditions of a restricted stock unit award agreement covering the grant."
A restricted stock unit (RSU) award agreement is a formal promise from a company that an employee or contractor will receive company shares (or cash equal to their value) after meeting certain conditions, such as staying with the company for a set time or hitting performance targets. Investors care because RSUs can dilute existing shares when converted, reveal how management is paid and incentivized, and signal future share issuance that can affect earnings and stock value.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to $32.81, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on April 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.
The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 3,200 of NewAmsterdam’s ordinary shares to two non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units were granted on April 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.
About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
What equity awards did NewAmsterdam (NAMS) grant on April 1, 2026?
NewAmsterdam granted 15,000 stock options and 3,200 restricted stock units to two non-executive hires. According to the company, the options carry an exercise price of $32.81 and the RSUs and options vest over multi-year schedules tied to continued service.
What is the exercise price of the NAMS inducement options and how was it set?
The exercise price for the inducement options is $32.81, equal to the April 1, 2026 closing price. According to the company, that closing market price on Nasdaq set the per-share exercise price for the options granted.
How do the NAMS stock options vest for the April 1, 2026 grants?
The options vest over four years with 25% after one year, then monthly for 36 months. According to the company, vesting is subject to each employee's continued service on each vesting date under the 2024 Inducement Plan.
What is the vesting schedule for the 3,200 RSUs granted by NewAmsterdam (NAMS)?
The 3,200 restricted stock units vest over three years with one-third each year. According to the company, each tranche vests on the one-, two- and three-year anniversaries, subject to continued employment and award agreement terms.
Under what plan and Nasdaq rule were the NAMS inducement awards approved?
The grants were approved under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). According to the company, the Compensation Committee approved the inducement awards as material to the hires' acceptance of employment.
